Advertisement

Topics

Roivant Splashes Cash Again To License GSK Skin Disorder Drug

08:44 EDT 13 Jul 2018 | SCRIP

The UK drug maker is tightening its R&D focus by selling on the psoriasis and atopic dermatitis investigational drug tapinarof...

      

Related Stories

 

Original Article: Roivant Splashes Cash Again To License GSK Skin Disorder Drug

NEXT ARTICLE

More From BioPortfolio on "Roivant Splashes Cash Again To License GSK Skin Disorder Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...